Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.
Also called NCT07824323
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 400 participants
- Sponsor
- Taipei Medical University Hospital
- Registry
-
NCT07824323
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Taiwan
- Registry status
- Recruiting
Technical summary
Registry record NCT07824323. Randomized; single masking; primary purpose treatment. Start 2026-08-26 (actual); primary completion 2028-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
- Acronym
- EARLY-BIRD ACS
- Condition
- Acute Coronary Syndromes
- Condition
- Dyslipidemia
- Intervention (Drug)
- bempedoic acid
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- High-Intensity Statin Therapy
- Lead sponsor
- Taipei Medical University Hospital
Record details
- Record id
cardio:ct-nct07824323- Content hash
c0c86c91621c5238d200feee6b4513da244c990abdbf94fd5d470893710653b6